These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 2297766

  • 1. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF, Lewis I, Ulchaker J, Stanley J, Tubbs R, Finke JH.
    Cancer Res; 1990 Feb 15; 50(4):1176-82. PubMed ID: 2297766
    [Abstract] [Full Text] [Related]

  • 2. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H, Lin KM, Chu TM.
    Cancer Res; 1990 Feb 15; 50(4):1107-12. PubMed ID: 2297759
    [Abstract] [Full Text] [Related]

  • 3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 4. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
    Puri RK, Travis WD, Rosenberg SA.
    Cancer Res; 1990 Sep 01; 50(17):5543-50. PubMed ID: 2386960
    [Abstract] [Full Text] [Related]

  • 5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 6. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ, Kern DE, Schultz KR, Greenberg PD, Cheever MA.
    J Immunol; 1988 May 15; 140(10):3679-85. PubMed ID: 2896213
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 8. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 9. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH.
    Cancer Res; 1989 Feb 15; 49(4):963-8. PubMed ID: 2521457
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
    Lin TH, Chu TM.
    Cancer Res; 1990 May 15; 50(10):3013-8. PubMed ID: 1970751
    [Abstract] [Full Text] [Related]

  • 11. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K, O'Donnell RW, Cockett AT.
    J Biol Response Mod; 1988 Feb 15; 7(1):43-53. PubMed ID: 3259620
    [Abstract] [Full Text] [Related]

  • 12. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
    Ujházy P, Maccubbin D, Eppolito C, Mihich E, Ehrke MJ.
    Lymphokine Cytokine Res; 1994 Apr 15; 13(2):99-106. PubMed ID: 8061121
    [Abstract] [Full Text] [Related]

  • 13. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A, Cameron RB, Rosenberg SA.
    J Immunol; 1990 Jun 01; 144(11):4463-71. PubMed ID: 2111349
    [Abstract] [Full Text] [Related]

  • 14. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M, Capdeville R, Combaret V, Zhou DC, Clapisson G, Banchereau J, Franks CR, Chouaib S, Blay JY, Philip T.
    Eur Cytokine Netw; 1990 Jun 01; 1(3):141-7. PubMed ID: 2129798
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS, Hargrove ME, Ting CC.
    J Immunol; 1988 Aug 15; 141(4):1390-7. PubMed ID: 3260924
    [Abstract] [Full Text] [Related]

  • 16. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
    Yang JC, Mulé JJ, Rosenberg SA.
    J Immunol; 1986 Jul 15; 137(2):715-22. PubMed ID: 2873187
    [Abstract] [Full Text] [Related]

  • 17. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN, Khoo NK, Lala PK.
    Cancer Res; 1992 Dec 01; 52(23):6452-62. PubMed ID: 1423293
    [Abstract] [Full Text] [Related]

  • 18. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS.
    Nat Immun Cell Growth Regul; 1990 Dec 01; 9(4):265-73. PubMed ID: 2120581
    [Abstract] [Full Text] [Related]

  • 19. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
    Pope BL, Chourmouzis E, Victorino L, MacIntyre JP, Capetola RJ, Lau CY.
    J Immunol; 1993 Sep 15; 151(6):3007-17. PubMed ID: 8376766
    [Abstract] [Full Text] [Related]

  • 20. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY, Ohnishi H, Chu TM.
    Mol Biother; 1989 Sep 15; 1(6):318-22. PubMed ID: 2610950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.